07:55 AM EST, 02/06/2025 (MT Newswires) -- Bausch + Lomb Corporation ( BLCO ) , a global eye health company, was at last look down 7% in US premarket trade on Thursday after it issued an update on a potential sale, which was disclosed in December 2024 following a regulatory request.

"Taking Bausch + Lomb ( BLCO ) private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc. ( BHC ) After engagement with potential buyers, that process is complete, and will not result in a transaction at this time," Thursday's statement said.

"Full separation remains the goal. Bausch + Lomb ( BLCO ) continues to operate as its own entity and execute on its strategies and business plan.

The company, which raised 2024 revenue guidance on October 30, will report fourth-quarter and full-year 2024 earnings on February 19, in addition to providing guidance for the 2025 fiscal year.

Bausch + Lomb ( BLCO ) is traded on both the New York Stock Exchange and Toronto Stock Exchange.